You are here

Article Text

Article menu
Download PDFPDF
Letter
Evidence to support or guide glucocorticoid tapering in rheumatoid arthritis is lacking

https://doi.org/10.1136/annrheumdis-2019-216009

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Handling editor Josef S Smolen

    • Contributors BIW: study conception and design, interpretation of data, drafting of the manuscript and final approval of the manuscript. DMW: data acquisition, critical revision of the manuscript and final approval of the manuscript. AKW: study conception, critical revision of the manuscript and final approval of the manuscript. DJC: study conception, critical revision of the manuscript and final approval of the manuscript.

    • Funding Dr. Wallace was supported during the time of this research by a VA Advanced Fellowship in Health Services Research and Development.

    • Competing interests Dr Clauw reports consulting relationships with Aptinyx, Daiichi Snakyo, Intec Pharma, EliLilly, Pfizer, Samumed, Theravance, Tonix, Zynerba; has served as expert witness for Nix Patterson LLP, Williams & Connolly LLP; receives research support from Aptinyx, Pfizer.

    • Patient consent for publication Not required.

    • Provenance and peer review Not commissioned; externally peer reviewed.